Mediolanum International Funds Ltd Grows Position in Insulet Corporation $PODD

Mediolanum International Funds Ltd increased its stake in Insulet Corporation (NASDAQ:PODD) by 121.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,050 shares of the medical instruments supplier’s stock after purchasing an additional 25,786 shares during the period. Mediolanum International Funds Ltd owned approximately 0.07% of Insulet worth $14,730,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Insulet by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock valued at $2,735,991,000 after buying an additional 39,403 shares in the last quarter. Geode Capital Management LLC increased its stake in Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after acquiring an additional 58,309 shares during the last quarter. American Century Companies Inc. raised its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Groupama Asset Managment lifted its stake in Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock worth $177,096,000 after purchasing an additional 27,408 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PODD. Sanford C. Bernstein restated an “outperform” rating on shares of Insulet in a research report on Friday. JPMorgan Chase & Co. increased their target price on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Oppenheimer increased their target price on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $379.45.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

Shares of PODD opened at $331.17 on Friday. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The company has a 50-day simple moving average of $322.22 and a two-hundred day simple moving average of $314.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $23.30 billion, a PE ratio of 100.66, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.